摘要
目的:探讨分析多西他赛联合顺铂行食管癌术前新辅助化疗对手术成功率的改善效果。方法:90例食管癌患者随机分为观察组及对照组,观察组45例接受术前新辅助化疗,对照组45例单纯手术治疗,观察疗效、手术切除率、并发症及1年生存率。结果:观察组总有效率、手术切除率及1年生存率分别为60.0%、97.8%及91.1%,对照组分别为33.3%、68.9%及62.2%(P<0.05)。并发症发生率无显著差异(P>0.05)。结论:食管癌患者采用多西他赛联合顺铂行术前新辅助化疗可提高临床效果、手术切除率及短期生存率,不增加并发症。
Objective:To investigate the effect of preoperative neoadjuvant chemotherapy by docetaxel and cisplatin on esophageal cancer. Methods:Ninety patients with esophageal cancer were randomly divided into observation group(n = 45) treated with preoperative neoadjuvant chemotherapy and control group(n = 45) treated with surgery only. The clinical efficacy,resection rate,surgical complications and 1-year survival rate were compared between two groups. Results:The total effective rate,resection rate and 1-year survival rate in observation group and control group were 60. 0% vs 33. 3%(P < 0. 05),97. 8% vs 68. 9%(P < 0. 05),91. 1% vs 62. 2%(P < 0. 05).There was no significant difference in complications between two groups(P > 0. 05). Conclusion:The preoperative neoadjuvant chemotherapy with docetaxel and cisplatin can effectively improve the clinical efficiency,resection rate and short-term survival rate for esophageal cancer patients,without more postoperative complications.
出处
《西北国防医学杂志》
CAS
2016年第12期789-791,共3页
Medical Journal of National Defending Forces in Northwest China
关键词
食管癌
多西他赛
顺铂
新辅助化疗
esophageal cancer
docetaxel
cisplatin
neoadjuvant chemotherapy
